Increased Procoagulant Activity of Red Blood Cells from Patients with Homozygous Sickle Cell Disease and β-Thalassemia
- 1 September 1996
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 76 (03) , 322-327
- https://doi.org/10.1055/s-0038-1650577
Abstract
It has recently been proved that, in vitro, red blood cells (RBCs) from patients with homozygous β-thalassemia behave as procoagulant cells. The procoagulant activity of β-thalassemia RBCs might be the result of an increased exposure of procoagulant phospholipids (i. e. phosphatidylserine) in the outer leaflet of the membrane. In order to test this hypothesis, we compared the catalytic properties of RBCs of patients with β-thalassemia and homozygous sickle cell disease (SS-RBCs) with that of controls. The catalytic parameters (Km, kcat) of prothrombin activation by factor Xa were determined both in the absence and in the presence of RBCs. The turn-over number (kcat) of the reaction was not modified by normal, SS- or (3-thalassemia RBCs. The Km was lower in the presence of normal RBCs (mean value: 9.1 µM) than in the absence of cells (26 µM). The Km measured in the presence of either SS-RBCs (mean value: 1.6 µM) or β-thalassemia RBCs (mean value: 1.5 pM) was significantly lower compared to normal RBCs (p <0.001). No significant difference was observed between SS-RBCs and p-thalassemia RBCs. Annexin V, a protein with high affinity and specificity for anionic phospholipids, inhibited the procoagulant activity of both SS-RBCs and (3-thalassemia RBCs, in a dose-dependent manner. More than 95% inhibition was achieved at nanomolar concentrations of annexin V. These results indicate that the procoagulant activity of both β-thalassemia RBCs and SS-RBCs may be fully ascribed to an abnormal exposure of phosphatidylserine at the outer surface of the red cells.Keywords
This publication has 16 references indexed in Scilit:
- Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Phospholipid binding of annexin V: Effects of calcium and membrane phosphatidylserine contentArchives of Biochemistry and Biophysics, 1992
- Plasma factor VII and thrombin–antithrombin III levels indicate increased tissue factor activity in sickle cell patientsBritish Journal of Haematology, 1992
- Platelet regulatory prostanoids and platelet release products in sickle cell diseaseAmerican Journal of Hematology, 1992
- Thromboembolic Complications in Beta Thalassemia majorActa Haematologica, 1992
- Transbilayer movement of phospholipids in red cell and platelet membranesBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1991
- Studies on sickled erythrocytes provide evidence that the asymmetric distribution of phosphatidylserine in the red cell membrane is maintained by both ATP-dependent translocation and interaction with membrane skeletal proteinsBiochimica et Biophysica Acta (BBA) - Biomembranes, 1988
- Prothrombin Salakta : An abnormal prothrombin characterized by a defect in the active site of thrombinThrombosis Research, 1984
- Abnormalities in membrane phospholipid organization in sickled erythrocytes.Journal of Clinical Investigation, 1981
- Erythrocyte Membrane Lipid Reorganization during the Sickling ProcessBritish Journal of Haematology, 1979